Maackiain Prevents Amyloid-Beta–Induced Cellular Injury via Priming PKC-Nrf2 Pathway

Na Lu, Guojun Tan, Hongling Tan, Xing Zhang, Yunling Lv, Xiujuan Song, Daofeng You, and Ziyuan Gao

1Department of Emergency Intensive Care Medicine, The First Hospital of Hebei Medical University, Shijiazhuang, China
2Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, China
3Department of Gastrointestinal Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
4Department of Emergency Intensive Care Medicine, The Second Hospital of Shijiazhuang City, Shijiazhuang, China

Correspondence should be addressed to Guojun Tan; tanguojun@hb2h.com

Received 2 May 2022; Accepted 22 May 2022; Published 22 June 2022

Amyloid-beta (Aβ) peptide induces neurotoxicity through oxidative stress and inflammatory response. Brain deposition of a large amount of amyloid-beta (Aβ), in particular Aβ42, promotes the development of Alzheimer’s disease (AD). Maackiain is extracted from traditional Chinese medicine peony root and possesses antioxidative, antiosteoporosis, antitumor, and immunoregulatory effects. Whether Maackiain can reduce neurotoxicity caused by Aβ accumulation remains elusive. Herein, we found that Maackiain downregulated Aβ42-induced cell injury and apoptosis in PC12 cells. Moreover, Maackiain prevented Aβ42 stimulation-induced generation of oxidative stress and reduced Aβ42-caused impairment of mitochondrial membrane potential in PC12 cells. Maackiain increased the superoxide dismutase activity and decreased malondialdehyde content that was induced by Aβ42. Mechanistic studies showed that Maackiain increased intranuclear Nrf2 expression. Consistently, Nrf2 silencing by RNA interference weakened the protective role of Maackiain against Aβ exposure. In addition, calphostin C, a specific antagonist of protein kinase C, attenuated the antioxidant and anti-inflammatory capabilities of Maackiain in PC12 cells. Collectively, Maackiain promoted Nrf2 activation through the PKC signaling pathway, thus preventing PC12 cells from Aβ-induced oxidative stress and cell injury, suggesting that Maackiain is a potential drug for AD treatment.

1. Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative disease and is characterized by senile plaques, neurofibrillary tangles, and loss of nerve cells and synapses [1]. Amyloid-beta (Aβ) especially Aβ42, is the main component of senile plaques and promotes the formation of neurofibrillary tangles and loss of synapses during the progression of AD leading to neuronal apoptosis [2, 3]. Oxidative stress and inflammatory response have been shown to contribute to Aβ42-induced neurotoxicity. Deposition of Aβ42 in the brain decreases mitochondrial redox activity and induces the generation of a mass of reactive oxygen species (ROS), leading to the occurrence of oxidative stress in the nervous system [4, 5]. Excessive oxidative stress reaction induces neural inflammatory response through multiple signaling pathways such as nuclear factor kappa B (NF-κB) pathways, thereby further worsening nervous system injury [4, 6, 7]. Therefore, prevention of oxidative stress and neuroinflammatory response is a potential approach for the development of AD neuroprotective drugs.

NF-E2-related factor 2 (Nrf2) functions as a pivotal transcription factor that modulates oxidative stress reaction. Nrf2 is sequestered in cytoplasm under physiological condition by direct binding to Kelch-like ECH-associated protein 1 (Keap1), which prevents the translocation and activity of Nrf2 [8]. In response to internal and external environment stress, such as increase of free oxygen radicals, Nrf2 is
livered from Keap1-Nrf2 complex and translocated into the nucleus, where it promotes the transcription of antioxidant genes [8]. Nrf2 plays an essential role in maintenance of the physiological states of the brain. Nrf2 knockout mice show proteasomal dysfunction and apoptosis in neuron, as well as age-related atrophy of the basal forebrain and neurobehavioral impairment [9, 10]. Nrf2 deregulation is strongly linked to the pathophysiology of AD. Nrf2 expression as well as its inactivation is decreased in the brain of AD patients [11]. In Aβ deposition-related APP/PS1 mice hippocampal Nrf2 expression is decreased [12]; however, injection of lentiviral vectors overexpressing Nrf2 into hippocampus remarkably increases the cognitive and learning abilities of the APP/PS1 mice [13]. In addition, the therapeutic effects of some antioxidants on APP/PS1 mice associated with Nrf2 activation [14–16]. Importantly Nrf2 has been demonstrated to prevent against Aβ-induced oxidative stress reaction and reduce inflammation during the pathological progression of AD [17]. Therefore, Nrf2-targeting drugs are promising in the clinical treatment of AD.

Maackiain, a typical isoflavonoid, is extracted from traditional Chinese medicine peony root. Maackiain possesses antioxidative [18], antiseptic [19], antitumor [20], and immunoregulatory properties [21]. Maackiain has recently been reported to exhibit beneficial effects on preventing and improving diabetes mellitus-related metabolic disturbance [18]. Moreover, Maackiain can reduce dopaminergic neuron damage and improve neurological deficits of Caenorhabditis elegans with Parkinson’s disease [22]. However, it remains to be explored whether Maackiain can alleviate Aβ-induced neurotoxicity. In the study, we investigated the therapeutic properties of Maackiain in treatment of oxidative stress and inflammation in PC12 cells exposed to Aβ and the underlying mechanisms. Our results demonstrate that Maackiain protects PC12 cells against Aβ exposure through Nrf2 activation in a PKC signaling pathway-dependent manner. Our findings highlight that Maackiain can provide a potential avenue for clinical treatment of AD.

2. Materials and Methods

2.1. Cell Culture. PC12 cells derived from rat pheochromocytoma were purchased from ATCC and cultured in RPMI 1640 culture medium (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum at 37°C in a 5% CO₂ incubator. Culture medium was refreshed every 3 days. Aβ42 (Abcam, cat # ab120301, USA) was dissolved in dimethyl sulfoxide (DMSO) to a final concentration of 1 mM and then incubated at 37°C for 4 days. Maackiain (Sigma-Aldrich) was dissolved into dimethyl sulfoxide to a concentration of 10 mM. Fresh PC12 cell culture medium was added 6 h prior to Aβ42 stimulation.

2.2. siRNA Transfection. Nrf2 and control siRNAs were transfected into PC12 cells in the presence of Lipofectamine 3000 (Invitrogen) according to the protocol provided by the manufacturer. Briefly, PC12 cells were inoculated into a 6-well plate and transfected with 50 nM siRNA when reaching 70-80% confluency.

2.3. Cell Counting Kit-8 (CCK-8) Assay. Cell viability of the PC12 cells was determined by CCK-8 assay as previously described [23]. Briefly, the cells were inoculated into a 96-well plate (2000 cells/well). After Maackiain treatment with or without Aβ exposure, CCK-8 solution (Sigma-Aldrich) was added into the medium, and the cells were incubated for additional 2 h. Absorbance at 450 nm was determined using a microplate reader (CANY, Shanghai, China).

2.4. Western Blot Analysis. Total cell protein was extracted by a Tris lysis buffer (50 mM Tris-base, 150 mM sodium chloride) with 1% Triton. The protein levels were determined by immunoblotting using specific antibodies according to a previous standard protocol [24]. Briefly, the samples were loaded by SDS polyacrylamide gel electrophoresis (PAGE), and then the protein was transferred onto a polyvinylidene fluoride membrane using a wet transfer method. Membranes were blocked using 5% nonfat dry milk in PBS for 1 hour. After washing with TBST, the membrane was incubated with primary rabbit anti-Nrf2, rabbit anti-p65, or anti-GAPDH polyclonal antibody (1: 1000; Abcam) at 4°C overnight. After washing with TBST, the membrane was incubated with horseradish peroxidase conjugate secondary antibody (Abcam) at room temperature for 2 hours. The protein bands were visualized using an ECL chemiluminescence detection kit (Abcam).

2.5. DCFH-DA Assay. Dichlorodihydrofluorescein diacetate (DCFH-DA) assay was performed to detect intracellular ROS level as previously described [25]. Briefly, PC12 cells were inoculated into a 6-well plate and added with 20 nM DCFH-DA. Following incubation in a 37°C incubator for 24 hours, the cells was observed and photographed under an Olympus IX73 fluorescence microscope.

2.6. Mitochondrial Membrane Potential Assay. PC12 cells were inoculated into a 6-well plate at 1 x 10⁶ cells/mL with 2 mL cell suspension per well and incubated with 5 μM rhodamine 123 (dissolved in dimethyl sulfoxide; Sigma-Aldrich) in 37°C for 45 minutes [26]. After washing, cells were collected by centrifugation at 1500 r/min for 5 minutes. Mean fluorescence intensity (MFI) was calculated using a flow cytometry.

2.7. SOD Activity and MDA Levels Measurement. Cells were lysed, and the supernatant was collected after centrifuged at 12000 g for 10 minutes. The intracellular SOD activity and MDA content were measured in strict accordance with the kit instructions (fiancheng, Nanjing, China) [27].

2.8. Detection of Lactate Dehydrogenase (LDH) Activity. Aβ-induced cell injury was assessed using LDH activity assay according to manufacturer’s instruction (Beyotime, China). Briefly, cell supernatant was incubated with reaction buffer and coenzyme I at 37°C for 15 minutes, followed by addition of 2,4-dinitrophenylhydrazine and incubation at 37°C for 15 minutes. After addition of 0.4 M NaOH and incubation for 5 minutes at room temperature, absorbance of cell supernatant at 450 nm was measured.
2.9. TUNEL Staining. A TUNEL apoptosis detection kit purchase from Beyotime was used to assess the cell apoptosis. PC12 cells were fixed using 4% paraformaldehyde at room temperature for 20 minutes followed by three times of wash with PBS for 5 minutes each time. After permeabilized with 1% Triton X-100, the cells were treated with 3% H$_2$O$_2$ for 10 minutes. After washing with PBS for three times, cells were incubated with TdT enzyme reaction solution containing Maackiain and exposed to Aβ$_{42}$ (10 μM) for additional 24 hours. CCK-8 (b) and LDH activity (c) assay were performed to detect the viability and injury severity in PC12 cells. TUNEL staining (d) and caspase-3 activity assay (e) were performed to assess the cell apoptosis. *P < 0.05 and **P < 0.01.

![Figure 1: Maackiain prevented Aβ$_{42}$-induced PC12 cell injury. (a) PC12 cells were stimulated by different doses of Aβ$_{42}$ (0, 0.1, 10, and 100 μM) for 24 hour or 10 μM Aβ$_{42}$ at different timepoints (0, 6, 12, 24, and 48 hours). CCK-8 assay was conducted to determine the cell viability in PC12 cells. (b) PC12 cells were stimulated by different doses of Maackiain (10, 20, and 50 μM) for 6 hours and then exposed to Aβ$_{42}$ (10 μM) for additional 24 hours. CCK-8 (b) and LDH activity (c) assay were performed to detect the viability and injury severity in PC12 cells. TUNEL staining (d) and caspase-3 activity assay (e) were performed to assess the cell apoptosis. *P < 0.05 and **P < 0.01.](image-url)
TRITC-5-dUTP in the dark for 60 minutes. The nuclei were stained using 4',6-diamidino-2-phenylindole (DAPI), and the fluorescence signal was visualized using a fluorescence microscope.

2.10. Statistical Analysis. All data are expressed as the mean ± SD. Analysis of variance and q test were used for comparison between groups. P < 0.05 was considered statistically significance.

3. Results

3.1. Maackiain Reduces Aβ42-Induced Cell Injury. In order to determine the toxicity, different concentrations of Aβ42 were tested on PC12 cells using the CCK-8 assay. The results showed that a dose-dependent toxic effects of Aβ42 on PC12 cells and treatment with 10 μM Aβ42 lead to reduction of cell viability to 50% of normal cells (Figure 1(a)). Further analysis showed 10 μM Aβ42-induced toxic effects on PC12 cells time dependently with a significant effect for 24 hours (Figure 1(b)). Therefore, 10 μM Aβ42 stimulation for 24 hours was selected as a condition to induce injury to PC12 cells for the following experiments. To determine the protective effects of Maackiain on cell injury induced by Aβ42, PC12 cells were pretreated with different doses of Maackiain (10, 20, and 50 μM) six hours before 10 μM Aβ42 stimulation. The results of CCK-8 and LDH activity assay showed that Maackiain prevented Aβ42-induced cell injury in a dose-dependent way (Figures 1(c) and 1(d)). The results of TUNEL staining demonstrated that Aβ42 induced apparent apoptosis in PC12 cells, which was remarkably reduced by treatment of Maackiain (Figure 1(e)). Moreover, Maackiain significantly inhibited Aβ42-induced caspase-3 activation in a concentration-dependent way (Figure 1(f)).

3.2. Maackiain Inhibits Aβ42-Induced Oxidative Stress in PC12 Cells. To clarify mechanisms underlying the amelioration of Aβ42-induced cell injury by Maackiain in PC12 cells, DCFH-DA assay was performed to determine intracellular ROS level. Aβ42-induced ROS accumulation in PC12 cells as indicated by green fluorescence. Maackiain significantly inhibited Aβ42-induced oxidative stress in a concentration-dependent way (Figure 2(a)). Flow cytometry analysis showed that Aβ42 decreased MMP in PC12 cells, and Maackiain restored intracellular MMP (Figure 2(b)). In addition, detection of intracellular SOD activity and MDA level revealed that Maackiain significantly abolished the decrease of SOD activity (Figure 2(c)) and increase of MDA levels induced by Aβ42 (Figure 2(d)).

![Figure 2: Maackiain abolished oxidative stress in PC12 cells stimulated with Aβ42. PC12 cells were stimulated by different doses of Maackiain (10, 20, and 50 μM) for 6 hours and then exposed to 10 μM Aβ42 for additional 24 hours, followed by determination of intracellular ROS level by DCFH-DA assay (a), mitochondrial membrane potential with rhodamine 123 coupled with flow cytometry (b), SOD activity (c), and MDA levels (d). *P < 0.05 and **P < 0.01.](image-url)
3.3. Maackiain Prevents Aβ42-Induced Inflammatory Response. To investigate whether Maackiain affects Aβ42-induced inflammatory response, we detected NF-κB activation in Aβ42-treated PC cells with or without Maackiain. The results showed that Aβ42 significantly promoted the translocation of p65, the key component of NF-κB complex.
in PC12 cells, which was obviously prevented by Maackiain (Figure 3(a)). Consistently, ELISA detection of TNF-α and IL-1β protein level in the supernatant of PC12 cells indicated that Maackiain reduced the TNF-α (Figure 3(b)) and IL-1β (Figure 3(c)) levels that was increased by Aβ42.

3.4. Maackiain Promotes Nrf2 Nuclear Translocation via the PKC Signaling Pathway. We further determined Nrf2 expression in PC12 cells treated with Maackiain. The results of western blot analysis revealed that Maackiain did not affect Nrf2 expression (Figure 4(a)). The results

**Figure 5:** Effects of Nrf2 siRNA and calphostin C on PC12 cell injury. (a) Nrf2 and control siRNAs were transfected into PC12 cells. At 24 hours after transfection, the Nrf2 levels in PC12 cells were determined by immunoblotting. Prior to Maackiain (100 μM) treatment, PC12 cells were transfected with Nrf2 siRNA or incubated with calphostin C for 1 hour and then exposed to Aβ42. CCK-8 (b) and LDH activity (c) assay were performed to detect cell viability and injury severity. Cell apoptosis was assessed by TUNEL staining (d) and caspase-3 activity assay (e). *P < 0.05 and **P < 0.01.
transfected with Nrf2 siRNA or incubated with calphostin C for 1 hour and then exposed to Aβ42. (a) MMP value was evaluated by rhodamine 123 staining. SOD activity and MDA levels (b) as well as TNF-α and IL-1β (c) were also assessed. *P < 0.05 and **P < 0.01.

of immunostaining showed that Nrf2 was present in the cytoplasm of PC12 cells, while Maackiain stimulation increased the intranuclear Nrf2 levels dose-dependently (Figure 4(b)), suggesting that Maackiain promotes the activation of Nrf2. After administration of PKC inhibitor calphostin C, the ability of Maackiain to promote intranuclear translocation of Nrf2 was weakened (Figure 4(b)).

3.5. Nrf2 Silencing or PKC Inhibition Attenuates the Neuroprotective Effects of Maackiain. To validate the involvement of Nrf2 and PKC in the cytoprotective effects of Maackiain, prior to Maackiain treatment, PC12 cells were transfected with Nrf2 siRNA or treated with calphostin C, followed by exposure to Aβ42. As shown in Figure 5(a), transfected with Nrf2 siRNA significantly decreased the protein levels of Nrf2 in PC12 cells. CCK-8 assay showed that Nrf2 siRNA and calphostin C decreased the cell viability compared to that treated with Maackiain plus Aβ42 (Figure 5(b)), while LDH activity was increased compared to the control group (Figure 5(c)). TUNEL staining found that Nrf2 siRNA and calphostin C treatment increased PC12 cell apoptosis (Figure 5(d)) and promoted the caspase-3 activities in PC12 cells (Figure 5(e)).

3.6. Nrf2 Silencing or PKC Inhibition Attenuates the Antioxidant and Anti-inflammatory Effects of Maackiain. To investigate the role of Nrf2 and PKC in Maackiain preventing against oxidative stress, prior to Maackiain treatment, PC12 cells were transfected with Nrf2 siRNA or incubated with calphostin C, followed by exposure to Aβ42.

DCFH-DA assay was performed to detect intracellular ROS. After Nrf2 siRNA and calphostin C treatment, MFI value in the PC12 cells was weaker than that in the scramble and control group (Figure 6(a)), respectively. Nrf2 siRNA and calphostin C pretreatment decreased SOD activity and increased MDA levels (Figure 6(b)), as well as upregulated TNF-α and IL-1β (Figure 6(c)) in Aβ42-stimulated PC12 cells.

4. Discussion

Peony root is a perennial herb that is widely used in traditional Chinese medicine. Various active ingredients, flavonoids, saponins, and polysaccharides, have been identified from the extracts of peony root. Maackiain is an important flavonoid of peony root. Maackiain has been shown to alleviate adipogenic activity [28] and improve metabolic disturbance rats with diabetes mellitus [18]. Moreover, Maackiain shows a neuroprotective role in Caenorhabditis elegans with Parkinson’s disease [22]. However, whether Maackiain can reduce Aβ42-induced neurotoxicity is unclarified. In this study, we showed that Maackiain reduced Aβ42-induced cell injury and apoptosis in PC12 cells. These findings suggest that Maackiain prevents Aβ42-induced neurotoxicity.

Aβ-induced oxidative stress plays an important role in the pathogenesis and development of AD [29]. Our results showed that Maackiain reduced ROS level as well as ΔΨm in PC12 cells. Importantly, we found that Maackiain prevented Aβ42-induced decrease of ΔΨm and SOD activity and increase of MDA content. The chronic inflammatory
response of the nervous system is another important pathological feature of AD and plays a key role in promoting AD progression. In vivo and in vitro studies have demonstrated that abnormal deposition of Aβ in the brain is an initiation factor of neuroinflammatory response in AD [30]. Aβ promotes the release of inflammatory factors by binding to receptors on the surface of microglia and other neuronal cells. Moreover, Aβ-induced oxidative stress indirectly enhances the activation of inflammatory pathways. In this study, we found that Aβ42 significantly increased the mRNA levels and secretion of TNF-α and IL-1β in PC12 cells, which was however reduced by Maackiain pretreatment. These results demonstrate that Maackiain protects PC12 cells from Aβ42 through reducing Aβ42-induced oxidative stress and neuroinflammatory response.

Guo et al. [18] and Bai et al. [19] found that Maackiain exhibits antioxidative effect through promoting Nrf2 activation. Results from this study demonstrated that Maackiain did not affect Nrf2 expression but significantly increased intranuclear Nrf2 expression. These results indicate that Maackiain promotes intranuclear translocation of Nrf2, which is consistent with the findings of previous studies [18, 19]. In this study, we further investigated whether Nrf2 is involved in the antioxidative and anti-inflammatory effects of Maackiain. Our results showed that Nrf2 silencing using RNA interference technology, the antioxidative and anti-inflammatory effects of Maackiain were significantly weakened, and the protective effects of Maackiain on PC12 cells exposed to Aβ were also reduced. These findings suggest that promotion of Nrf2 nuclear translocation contributes to the antioxidative stress and anti-inflammatory effects of Maackiain.

Some protein kinases phosphorylate Nrf2 to alter its conformation and facilitate its separation from Keap1 [31]. PKC is a multifunctional serine/threonine kinase downstream of G protein-coupled receptor and is involved in various biochemical processes including the regulation of transcription factors [32, 33]. It has been reported that PKC can phosphorylate Nrf2 at Ser40 leading to Nrf2 dissociation from Keap1, entrance into the nucleus and promotion of antioxidant gene transcription [34, 35]. In this study, we showed that PKC-specific inhibitor calphostin C inhibited Maackiain in the intranuclear translocation of Nrf2. Moreover, calphostin C inhibited the effects of Maackiain on Aβ42-induced alteration of PC12 cell membrane potential, MDA content, and TNF-α and IL-1β levels and weakened the protective effects of Maackiain on cell viability.

Taken all together, our results demonstrated that Maackiain reduced Aβ42-induced oxidative stress, inflammatory responses, cell injury, and apoptosis in PC12 cells in a dose-dependent manner. Our results also revealed that Maackiain promoted Nrf2 intranuclear translocation through the PKC signaling pathway, and inhibiting PKC signaling pathway or knocking down Nrf2 weakened the antioxidative stress and anti-inflammatory effects of Maackiain. Our results suggest that Maackiain can prevent against Aβ42-induced neurotoxicity and holds promise to be used as a potential drug for AD treatment in the clinic.

Data Availability
All data used to support the findings of this study are included within the article.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
This study is supported by the Project of Hebei Provincial Health Commission (20190416) and the Hebei Provincial Science and Technology Plan (19277793D).

References
[1] P. Scheltens, K. Blennow, M. M. B. Breteler et al., “Alzheimer’s disease,” Lancet, vol. 389, no. 10043, pp. 505–517, 2016.
[2] J. X. Lu, W. Qiang, W. M. Yau, C. D. Schwieters, S. C. Meredith, and R. Tycko, “Molecular structure of β-amyloid fibrils in Alzheimer’s disease brain tissue,” Cell, vol. 154, no. 6, pp. 1257–1268, 2013.
[3] X. Sun, W. D. Chen, and Y. D. Wang, “β-Amyloid: the key peptide in the pathogenesis of Alzheimer’s disease,” Frontiers in Pharmacology, vol. 6, p. 221, 2015.
[4] H. Kadowaki, H. Nishihori, F. Urano et al., “Amyloid β induces neuronal cell death through ROS-mediated ASK1 activation,” Cell Death and Differentiation, vol. 12, no. 1, pp. 19–24, 2005.
[5] T. Schilling and C. Eder, “Amyloid-β-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia,” Journal of Cellular Physiology, vol. 226, no. 12, pp. 3295–3302, 2011.
[6] E. Tamagno, G. Robino, A. Obbili et al., “H2O2 and 4-hydroxynonenal mediate amyloid β-induced neuronal apoptosis by activating jnks and p38,” Experimental Cell Research, vol. 180, no. 2, pp. 144–155, 2003.
[7] P. C. Bello-Medina, D. A. Gonzalez-Franco, I. Vargas-Rodriguez, and S. Diaz-Cintia, “Oxidative stress, the immune response, synaptic plasticity, and cognition in transgenic models of Alzheimer disease,” Neurology (Engl Ed), 2021.
[8] H. Li, Q. Zhang, W. Li et al., “Role of Nrf2 in the antioxidation and oxidative stress induced developmental toxicity of honokiol in zebrafish,” Toxicology and Applied Pharmacology, vol. 373, pp. 48–61, 2019.
[9] C. S. Lee, C. Lee, T. Hu et al., “Loss of nuclear factor E2-related factor 1 in the brain leads to dysregulation of proteasome gene expression and neurodegeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 20, pp. 8408–8413, 2011.
[10] H. Muramatsu, F. Katsuoka, K. Toide, Y. Shimizu, S. Furusako, and M. Yamamoto, “Nrf2 deficiency leads to behavioral, neurochemical and transcriptional changes in mice,” Genes to Cells, vol. 18, no. 10, pp. 899–908, 2013.
[11] C. P. Ramsey, C. A. Glass, M. B. Montgomery et al., “Expression of Nrf 2 in neurodegenerative diseases,” Journal of Neuropathology and Experimental Neurology, vol. 66, no. 1, pp. 75–85, 2007.
[12] K. Kanninen, T. M. Malm, H. K. Jyrkkänen et al., “Nuclear factor erythroid 2-related factor 2 protects against beta amyloid,”
Molecular and Cellular Neurosciences, vol. 39, no. 3, pp. 302–313, 2008.

[13] K. Kanninen, R. Heikkinen, T. Malm et al., "Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer’s disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 38, pp. 16505–16510, 2009.

[14] Y. Liu, Y. Deng, H. Liu, C. Yin, X. Li, and Q. Gong, "Hydrogen sulfide ameliorates learning memory impairment in APP/PS1 transgenic mice: a novel mechanism mediated by the activation of Nrf2," Pharmacology, Biochemistry, and Behavior, vol. 150-151, pp. 207–216, 2016.

[15] C. Y. Wang, Z. Y. Wang, J. W. Xie et al., "DI-3-n-butylphthalide-induced upregulation of antioxidant defense is involved in the enhancement of cross talk between CREB and Nrf2 in an Alzheimer’s disease mouse model," Neurobiology of Aging, vol. 38, pp. 32–46, 2016.

[16] Y. Hong and Z. An, "Hesperidin attenuates learning and memory deficits in APP/PS1 mice through activation of Akt/Nrf2 signaling and inhibition of RAGE/NF-kB signaling," Archives of Pharmacal Research, vol. 41, no. 6, pp. 655–663, 2018.

[17] K. N. Prasad, "Simultaneous activation of Nrf2 and elevation of antioxidant compounds for reducing oxidative stress and chronic inflammation in human Alzheimer’s disease," Mechanisms of Ageing and Development, vol. 153, pp. 41–47, 2016.

[18] J. Guo, J. Li, H. Wei, and Z. Liang, "Maackiain protects the kidneys of type 2 diabetic rats via modulating the Nrf2/HO-1 and TLR4/NF-kB/Caspase-3 pathways," Drug Design, Development and Therapy, vol. Volume 15, pp. 4339–4358, 2021.

[19] X. Bai, Y. Zhu, J. Jie, D. Li, L. Song, and J. Luo, "Maackiain protects against sepsis via activating AMPK/Nrf2/HO-1 pathway," International Immunopharmacology, vol. 108, p. 108710, 2022.

[20] F. Peng, L. Wang, L. Xiong, H. Tang, J. du, and C. Peng, "Maackiain modulates miR-374a/GADD45A axis to inhibit triple-negative breast cancer initiation and progression," Frontiers in Pharmacology, vol. 13, article 806869, 2022.

[21] Y. Liu, W. Zeng, C. Ma et al., "Maackiain dampens osteoclastogenesis via attenuating RANKL-stimulated NF-kB signalling pathway and NFATc1 activity," Journal of Cellular and Molecular Medicine, vol. 24, no. 21, pp. 12308–12317, 2020.

[22] R. T. Tsai, C. W. Tsai, S. P. Liu et al., "Maackiain ameliorates 6-hydroxydopamine and SNCA pathologies by modulating the PINK1/Parkin pathway in models of Parkinson's disease in Caenorhabditis elegans and the SH-SY5Y cell line," International Journal of Molecular Sciences, vol. 21, no. 12, p. 4455, 2020.

[23] C. Wang, J. Luo, X. Bai et al., "Calycosin alleviates injury in airway epithelial cells caused by PM 2.5 exposure via activation of AMPK signalling," Evidence-based Complementary and Alternative Medicine, vol. 2021, Article ID 8885716, 9 pages, 2021.

[24] L. Song, Y. Xie, C. Li et al., "The Legionella effector SdjA is a bifunctional enzyme that distinctly regulates phosphoribosyl ubiquitination," MBio, vol. 12, no. 5, article e0231621, 2021.

[25] L. Song, D. Li, Y. Gu, X. Li, and L. Peng, "Let-7a modulates particulate matter (≤ 2.5 μm)-induced oxidative stress and injury in human airway epithelial cells by targeting arginase 2," Journal of Applied Toxicology, vol. 36, no. 10, pp. 1302–1310, 2016.

[26] Y. Zhu, C. Wang, J. Luo et al., "The protective role of Zingerone in a murine asthma model via activation of the AMPK/Nrf2/HO-1 pathway," Food & Function, vol. 12, no. 7, pp. 3120–3131, 2021.

[27] Z. Wen, W. Hou, W. Wu et al., "6-O-Galloylpaeoniflorin Attenuates Cerebral Ischemia Reperfusion-Induced Neuroinflammation and Oxidative Stress via PI3K/Akt/Nrf2 Activation," Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 8678267, 14 pages, 2018.

[28] S. G. Mladenova, M. S. Savova, A. S. Marchev et al., “Anti-adipogenic activity of maackiain and ononin is mediated via inhibition of PPAR γ in human adipocytes,” Biomedicine & Pharmacotherapy, vol. 149, p. 112908, 2022.

[29] J. Vina, A. Lloret, R. Orts, and D. Alonso, "Molecular bases of the treatment of Alzheimer’s disease with antioxidants: prevention of oxidative stress," Molecular Aspects of Medicine, vol. 25, no. 1-2, pp. 117–123, 2004.

[30] M. Verri, O. Pastoris, M. Dossena et al., “Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer’s disease,” International Journal of Immunopathology and Pharmacology, vol. 25, no. 2, pp. 345–353, 2012.

[31] S. K. Niture, R. Khatri, and A. K. Jaiswal, "Regulation of Nrf2—an update," Free Radical Biology & Medicine, vol. 66, pp. 36–44, 2014.

[32] D. Mochly-Rosen, K. Das, and K. V. Grimes, "Protein kinase C, an elusive therapeutic target?", Nature Reviews. Drug Discovery, vol. 11, no. 12, pp. 937–957, 2012.

[33] S. Sanchez-Bautista and F. E. Nicolas, "Recent patents concerning modulators of protein kinase C, " Recent Patents on DNA & Gene Sequences, vol. 7, no. 1, pp. 74–81, 2013.

[34] H. C. Huang, T. Nguyen, and C. B. Pickett, "Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 23, pp. 12475–12480, 2000.

[35] H. C. Huang, T. Nguyen, and C. B. Pickett, "Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription," The Journal of Biological Chemistry, vol. 277, no. 45, pp. 42769–42774, 2002.

[36] H. C. Huang, T. Nguyen, and C. B. Pickett, "Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription," The Journal of Biological Chemistry, vol. 277, no. 45, pp. 42769–42774, 2002.